摘要
【目的】探索建立小剂量(1×106)人急性红白血病K562细胞株的NOD/SCID小鼠动物模型及通过流式细胞仪对NOD/SCID小鼠的肿瘤负荷情况进行评价的可行性。【方法】实验组NOD/SCID小鼠分别经尾静脉接种K562细胞1×106、5×106,比较不同剂量接种实验组小鼠的生存时间、组织病理改变及通过流式细胞术对NOD/SCID小鼠体内的肿瘤标记进行检测。【结果】1×106及5×106K562细胞接种的NOD/SCID小鼠的生存时间分别为(30.3±4.3)d和(22.2±3.7)d;其外周血、骨髓及肝、肺组织匀浆中均可发现不同比例的肿瘤细胞;通过流式细胞术检测5×106K562细胞接种组NOD/SCID小鼠外周血、肝匀浆中人CD13表达水平显著高于1×106接种组,而肺匀浆的CD13表达水平两组无显著性差异。【结论】小剂量(1×106)K562细胞NOD/SCID小鼠动物模型的建立是完全可行的,这有助于降低实验成本。
[Objective] To explore the feasibility of establishment of NOD/SCID mice model using microdose （1×10^6） erythroleukemia K562 ceils and to evaluate tumor load by flow cytometry. [Methods] NOD/SCID mice divided into two groups, inoculated with 1×10^6 and 5×10^6 K562 cells by tail vein, compare the survival rate, histopathology changes in different groups. The tumor marker in the body of NOD/SCID mice was monitored by flow cytometry. [Results] The survival time of NOD/SCID mice that inoculated with 1×10^6 and 5×10^6 K562 cells were （30.3±4.3） days and （22.2±3.7） days, respectively. There were various proportion of tumor ceils in the peripheral blood, bone marrow, and the liver or lung homogenate of the experimental groups. The tumor marker CD13 in the peripheral blood and liver homogenate of 5×10^6 K562 cells inoculated NOD/SCID mice group significantly higher than that in 1×10^6 group, but there was no significant difference of CD13 in the lung homogenate between the two groups. [Conclusion] Microdose tumor cells inoculation （1 ×10^6 tumor cells/per mice） can be used to establish an animal model of human leukemia in NOD/SCID mice successfully, this may contribute to minimize the experimental cost.
出处
《中山大学学报（医学科学版）》
CAS
CSCD
北大核心
2005年第5期523-527,共5页
Journal of Sun Yat-Sen University:Medical Sciences
基金
广东省自然科学基金资助项目(031707)
中山大学附属第二医院医学科研青年启动基金(200240489)
